Literature DB >> 19730179

Fulminant hepatic failure in children: superior and durable outcomes with liver transplantation over 25 years at a single center.

Douglas G Farmer1, Robert S Venick, Sue V McDiarmid, John P Duffy, Omar Kattan, Johnny C Hong, Jorge Vargas, Hasan Yersiz, Ronald W Busuttil.   

Abstract

OBJECTIVE(S): Death occurs in half of all children with fulminant hepatic failure (FHF). Although liver transplantation (LT) is potentially life-saving, there are only a few published series with limited experience. The aim was to examine predictors of survival after LT for FHF.
METHODS: Between 1984 and 2008, all LT for FHF performed in recipients less than or equal to 18 years of age were analyzed from a prospectively maintained database using 35 demographic, laboratory, and operative variables. Unique calculated variables included creatinine clearance (cCrCl) and Pediatric End-Stage Liver Disease score (PELD). Study end-points were patient and death censored graft survival. Median follow-up was 98 months. Statistical analysis involved the log-rank test and Cox proportional hazards model.
RESULTS: A total of 122 children underwent 159 LTx. Cryptogenic was the primary etiology (70%) and the median age was 53 months. The significant (P < 0.05) univariate predictors of worse graft survival were: recipient age <24 months, cCrCl <60 mL/min/1.73m, PELD >25 points, and warm ischemia time >60 minutes. The significant (P < 0.05) univariate predictors of worse patient survival were: recipient African-American and Asian race, recipient age <24 months, cCrCl <60 mL/min/1.73m, and time from onset jaundice to encephalopathy <7 days. On multivariate analysis, survival was significantly impacted by 4 variables: cCrCl <60 mL/min/1.73m (GRAFT and PATIENT), PELD >25 points (GRAFT), recipient age <24 months (GRAFT), and time from onset jaundice to encephalopathy <7 days (PATIENT). While overall 5- and 10-year survival was 73% and 72% (GRAFT) and 77% and 73% (PATIENT), these were significantly worse when a combination of multivariate risk-factors were present.
CONCLUSIONS: This data from a large, single-center experience demonstrates that LT is the treatment of choice for FHF and results in durable survival. Analysis revealed 4 novel outcome predictors. Young children with rapid onset acute liver failure are a high-risk subpopulation. Unique to this study, cCrCl and PELD accurately predicted the end-points. This analysis identifies patient subpopulations requiring early aggressive intervention with LT.

Entities:  

Mesh:

Year:  2009        PMID: 19730179     DOI: 10.1097/SLA.0b013e3181b480ad

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Molecular Absorbent Recirculating System therapy (MARS®) in pediatric acute liver failure: a single center experience.

Authors:  Pierre Bourgoin; Aicha Merouani; Véronique Phan; Catherine Litalien; Michel Lallier; Fernando Alvarez; Philippe Jouvet
Journal:  Pediatr Nephrol       Date:  2013-12-06       Impact factor: 3.714

Review 2.  Management and prognosis of acute liver failure in children.

Authors:  Daniel D'Agostino; Silvia Diaz; Maria Camila Sanchez; Gustavo Boldrini
Journal:  Curr Gastroenterol Rep       Date:  2012-06

3.  Pediatric chronic liver failure-sequential organ failure assessment score and outcome of acute liver failure in children.

Authors:  Bassam Abdel Hakam Ayoub; Mohammed Abdel Hafez Ali; Tahany Abdel Hamid Salem; Marwa Sabry Rizk; Salma Abdel Megeed Nagi; Nermin Mohammed Adawy
Journal:  Clin Exp Hepatol       Date:  2020-09-18

Review 4.  Liver transplantation in acute liver failure: A challenging scenario.

Authors:  Manuel Mendizabal; Marcelo Oscar Silva
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  Mesenchymal stem cells increase expression of heme oxygenase-1 leading to anti-inflammatory activity in treatment of acute liver failure.

Authors:  Zhi-Heng Zhang; Wei Zhu; Hao-Zhen Ren; Xin Zhao; Shuai Wang; Hu-Cheng Ma; Xiao-Lei Shi
Journal:  Stem Cell Res Ther       Date:  2017-03-20       Impact factor: 6.832

6.  Comparison of Two Donor Liver Procurement Methods for Treatment of Pediatric Acute Liver Failure.

Authors:  Jiahao Pei; Conghuan Shen; Ruidong Li; Yifeng Tao; Lu Lu; Weiming Chen; Xinbao Xie; Zhengxin Wang
Journal:  Front Pediatr       Date:  2022-03-03       Impact factor: 3.418

7.  Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure.

Authors:  Yu-Bao Zheng; Xiao-Hong Zhang; Zhan-Lian Huang; Chao-Shuang Lin; Jing Lai; Yu-Rong Gu; Bin-Liang Lin; Dong-Ying Xie; Shi-Bin Xie; Liang Peng; Zhi-Liang Gao
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

Review 8.  Management of Acute Liver Failure: A Pediatric Perspective.

Authors:  Heli Bhatt; Girish S Rao
Journal:  Curr Pediatr Rep       Date:  2018-05-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.